Advertisement

Topics

Lundbeck Inc. Company Profile

17:41 EDT 23rd September 2017 | BioPortfolio

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-need treatments. The company is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available. For more information, please visit www.lundbeckinc.com.


News Articles [61 Associated News Articles listed on BioPortfolio]

H. Lundbeck A/S: Lundbeck increases its share capital by 470,889 shares (0.2373 % of outstanding shares) as a result of exercise of employee warrants

Valby, Denmark, 2017-08-22 10:47 CEST (GLOBE NEWSWIRE) -- Valby, Denmark, 22 August 2017 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 2,354,...

H. Lundbeck-Aktie: Abgang zweier Top-Manager sorgt für Kurssturz - Aktienanalyse

Schwarzach am Main - H. Lundbeck-Aktienanalyse von "ZertifikateJournal": Kare Schultz wechselt von H. Lundbeck (ISIN: DK0010287234, WKN: 922351, Ticker-Symbol: LDB, Nasdaq OTC-Symbol: HLUKF) zu TEV...

Teva poaches Lundbeck's Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

US nod for injectable bipolar drug a welcome boost for Lundbeck

Danish CNS specialist Lundbeck and Japan’s Otsuka Pharmaceutical have announced that Abilify Maintena…

Lundbeck obtains rights to breakthrough research in Alzheimer’s disease

Danish CNS specialist Lundbeck has entered into an agreement with Israel-based biotech company ImmunoBrain…

Lundbeck plunges as Teva poaches its CEO

Danish CNS specialist Lundbeck saw its shares drop 11.58% to 364.20 Danish kroner this morning, when…

Lundbeck shares slip after FDA rebuff

Shares in Danish CNS specialist Lundbeck have fallen 4% on the news that the company, together with development…

H. Lundbeck A/S Strategy, SWOT and Corporate Finance Report [Updated: 04052017] Prices from USD $175

H. Lundbeck A/S Strategy, SWOT and Corporate Finance ReportSummaryH. Lundbeck A/S Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report c...

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Neoprofen [Lundbeck Inc.]

These highlights do not include all the information needed to use NeoProfen safely and effectively. See full prescribing information for NeoProfen. NeoProfen (ibuprofen lysine) Injection for intraveno...

Panhematin [Lundbeck Inc.]

Panhematin Hemin For Injection Rx only For intravenous infusion only.

Atryn [Lundbeck Inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for rec...

Peganone [Lundbeck Inc.]

PEGANONE 250 mg Tablets (ethotoin tablets, USP) R Only

Cogentin [Lundbeck Inc.]

Cogentin® (benztropine mesylate injection) Rx only

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in ...

Companies [16 Associated Companies listed on BioPortfolio]

Lundbeck LLC

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain dis...

Lundbeck Inc.

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-ne...

Lundbeck

Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D effort...

Psychotropics

The Lundbeck Institute is pleased to present Psychotropics Online, a comprehensive guide to CNS compounds and products.We have published Psychotropics since the 1960s in a printed handbook version, an...

Lundbeck Limited

As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmac...

More Information about "Lundbeck Inc." on BioPortfolio

We have published hundreds of Lundbeck Inc. news stories on BioPortfolio along with dozens of Lundbeck Inc. Clinical Trials and PubMed Articles about Lundbeck Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lundbeck Inc. Companies in our database. You can also find out about relevant Lundbeck Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Corporate Database Quicklinks



Searches Linking to this Company Record